# Formulary Sub-Committee Meeting Minutes November 5, 2019 – 1:00 p.m.

Members	Other Participants
Dr. Natalie Vanek *	Rachel Sanor, Manager, THMP*
Ruston Taylor *	Lester Mattson, DSHS Pharmacy
Dr. Gloria Heresi *	Liza Hinojosa, UT- Austin*
Ray Moore *	Robin Atwood, UT-Austin
Margaret Adjei PharmD. RPh. *	

#### Welcome

• Margaret Adjei PharmD. RPh. – MAC member

#### **Update on Medications**

• Per Rachel - No updates on approval of HIV meds and no updates on Hep B meds

#### **Discussion on Zypitamag and Livalo**

- These medications were presented at the last Medication Advisory Committee meeting.
- No other medication requests to be considered at this time

# Formulary Sub-Committee Meeting Minutes December 3, 2019 – 1:00 p.m.

Members	Other Participants
Dr. Natalie Vanek $$	Rachel Sanor, Manager, THMP√
Ruston Taylor $\checkmark$	Lester Mattson, DSHS Pharmacy $$
Dr. Gloria Heresi √	Liza Hinojosa, UT- Austin√
Ray Moore	Robin Atwood, UT-Austin
Margaret Adjei PharmD. RPh. $$	Mary Richards, Pharmacy Coordinator, THMP $$

#### **Program Updates**

- Top Ten medications and Hepatitis B meds have received approval from the DSHS Commissioner
  - Next steps the Medical Certification Form will need to be revised/updated

## **Revision of Medication Certification Form (MedCert - MCF)**

- The subcommittee discussed possibilities for revising the Medical Certification Form.
  - Mary Richards, Ruston Taylor, and Lester Mattson will work on revising form

### **Update on Medications**

- Cabotegravir LA (Long-acting Injectable) was discussed by the sub-committee. Topics included:
  - The need to have a mechanism/infrastructure to get meds out in a timely manner and what this would look like.
  - How the injections would work with RW payments.
  - Have Brian Rosemond, RN, DSHS Nurse Consultant provide insight on payment options since injectables require multiple visits
  - May require two different administrations
  - Estimated to be approved by FDA in January
  - May require a specialty pharmacy with infusion site
- FLAIR (First Long-Acting Injectable Regimen) was discussed by the sub-committee.

# Medications the Formulary Sub-committee will recommend for removal at the January Medication Advisory Committee meeting

- Cobicistat
- Elvitegravir
- Fuzeon

#### Next sub-committee meeting: January 7th 1:00 p.m.

Agenda

- Long acting meds
- Utilization of 90-day supply